FINANCE ministers from the G20 economies gathered today (9) in Venice, with global tax reform at the top of the meeting agenda.
The current meeting is being convened under the presidency of Italy.
US treasury secretary Janet Yellen, European Central Bank (ECB) chief Christine Lagarde and Russian finance minister Anton Siluanov were among those attending the meeting.
However, China and India have opted for a virtual presence in the meeting.
The G20 countries have already signed up to a framework for reform agreed on July 1 among members of the Organisation for Economic Cooperation and Development (OECD), which proposed a global minimum corporation tax rate of 15 per cent.
The member nations now seek a political deal to help the agreement, which would eventually end tax havens offered by some countries to attract global companies.
"Now is the time for the international community to rally together and build on this momentum to ensure we get the deal's final details over the line by October," British chancellor Rishi Sunak said as he set off for Venice.
Under the tax reform, other aim is to tax multinationals where they make their profits, not where they are headquartered. The move is particularly aimed at technology giants such as Google, Amazon, Facebook and Apple, which pay a meagre amount of tax compared to their income.
Meanwhile, a final agreement on the tax reforms is unlikely before the G20 leaders' summit in Rome in October, the Venice talks will enable thrashing out further details.
So far, the proposal has been backed by 131 countries.
EU members Estonia, Hungary and Ireland, which have all used low tax rates to attract investment, are among the hold-outs, while several countries such as the US and Germany are pushing for a higher rate than 15 per cent.
"Fifteen per cent for the minimum taxation on a corporate tax is a minimum, and France aims of having more than 15 per cent", French finance minister Bruno Le Maire told Bloomberg TV on Friday (9).
The G20 ministers are also expected to support an initiative by the International Monetary Fund (IMF) to increase aid to the most vulnerable countries through the allocation of $650 billion (£469bn) of special drawing rights.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.